Calypte Biomedical (CBMC) 10-Q 2008 Q2 Quarterly report

CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Calypte Biomedical Corporation (the “Company”) for the quarterly period ended June 30, 2008 (the “Report”), Donald N. Taylor, Chief Executive Officer of the Company, and Jerrold D. Dotson, Vice President - Finance and Administration of the Company, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)to my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Donald N. Taylor

Donald N. Taylor

Chief Executive Officer

August 14, 2008

/s/ Jerrold D. Dotson

Jerrold D. Dotson

Vice President – Finance and Administration

August 14, 2008

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Calypte Biomedical Corporation and will be retained by Calypte Biomedical and furnished to the Securities and Exchange Commission or its staff upon request.